Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Jul;77(5):385-394.
doi: 10.1080/00015385.2021.1948715. Epub 2021 Jul 20.

Pentraxin 3 concentration is associated with poor outcomes in patients with coronary artery disease: a systematic review and dose-response meta-analysis

William Kamarullah  1 , Nurcahyani  2 , Rachmatu Bill Multazam  3 , Claudia Mary Josephine  3
Affiliations
Meta-Analysis

Pentraxin 3 concentration is associated with poor outcomes in patients with coronary artery disease: a systematic review and dose-response meta-analysis

William Kamarullah et al. Acta Cardiol. 2022 Jul.

Abstract

Background: The amount of plasma pentraxin 3 (PTX3) is gradually being considered as a novel biomarker in forecasting poor clinical outcomes in patients with coronary artery disease (CAD). However, very little is known about the connection between PTX3 and CAD. This dose-response meta-analysis was carried out to quantify the relationship between circulating PTX3 concentration and CAD prognosis.

Methods: A systematic literature search was conducted using PubMed, EuropePMC, ProQuest, EBSCOhost, SCOPUS, Cochrane Library, and Google Scholar up until April 2021. The primary outcome of this study consisted of mortality and major adverse cardiovascular events (MACEs).

Results: The current meta-analysis comprised 15 studies with a total of 11.365 participants. High circulating PTX3 concentrations were associated with a higher risk of composite poor outcomes as compared to low circulating PTX3 concentrations (OR: 1.36 [1.18, 1.54], p < 0.001; I2 = 86.69%, Pheterogeneity<0.001), mortality (OR: 1.43 [1.15, 1.71], p < 0.001; I2 = 87.58%, Pheterogeneity<0.001), and MACEs (OR: 1.28 [1.08, 1.48], p < 0.001; I2 = 35.86%, Pheterogeneity = 0.08) in patients with CAD. Consistent results were obtained during meta-regression analyses and in all examined subgroups. The adjusted odds ratios (aORs) for composite poor outcomes increased by 32% per 1 ng/mL increment (OR: 1.32 [1.21, 1.43]) in line with the dose-response meta-analysis.

Conclusion: A significant positive dose-dependent association between circulating PTX3 concentration and the risk of poor outcomes in patients with CAD was found in this dose-response meta-analysis.

Keywords: MACEs; Pentraxin 3 (PTX3); coronary artery disease; meta-analysis; mortality; prognosis.

PubMed Disclaimer